Results 91 to 100 of about 112,336 (261)
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial
Arthritis &Rheumatology, EarlyView.Objective
Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie +14 morewiley +1 more sourceImpact of Atrial Fibrillation on the Risk of Thrombosis and Bleeding for Patients With Polycythemia Vera and Essential Thrombocytosis in the Real World
American Journal of Hematology, EarlyView.Rodrigo Ortega Perez, Luis Manuel Domínguez Rodríguez, Francisca Ferrer‐Marín, Beatriz Cuevas Ruíz, Clara Martínez Valverde, Patricia Vélez Tenza, María Isabel Mata Vázquez, Adrián Segura Díaz, María Laura Fox, Elvira Mora, Manuel Mateo Pérez Encinas, Mercedes Gasior Kabat, Gonzalo Carreño‐Tarragona, Rafael Andrés del Orbe, Gonzalo Caballero‐Navarro, Elena Magro Mazo, Ana Pardo Sanz, José Luis Zamorano Gómez, Alberto Álvarez Larrán, Valentín Garcia‐Gutierrez +19 morewiley +1 more sourceFunctional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Prospective Cohort Study
Arthritis &Rheumatology, EarlyView.Objective
To examine the association between radiographic structural damage and physical function (PF) in psoriatic arthritis (PsA). Methods
Data were analyzed from a large longitudinal PsA cohort. PF was measured using the Health Assessment Questionnaire (HAQ, 0–3) and Short Form‐36 PF subscale (SF‐36, 0–100); radiographic joint damage was measured ...Pankti Mehta, Shangyi Gao, Virginia Carrizo Abarza, Fadi Kharouf, Daniel Pereira, Richard J. Cook, Dafna D. Gladman, Vinod Chandran, Denis Poddubnyy +8 morewiley +1 more sourceCombination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study
Arthritis &Rheumatology, EarlyView.Objective
To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods
Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) + Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin +12 morewiley +1 more sourceAutoantibodies to Joint‐Related Peptides Are Associated With Onset of Rheumatoid Arthritis in Presymptomatic Seronegative Individuals
Arthritis &Rheumatology, EarlyView.Objective
To identify autoantibodies in presymptomatic individuals that associate with the onset of rheumatoid arthritis (RA) and to distinguish early RA from osteoarthritis (OA), particularly in individuals lacking classic RA serologic markers. Methods
We analyzed serum and plasma from three cohorts: presymptomatic individuals who later developed RA ...Outi Sareila, Linda Johansson, Anders Lundquist, Monica Leu Agelii, Lei Cheng, Yibo He, Erik Lönnblom, Maria Andersson, Jan Kihlberg, Anders Esberg, Inger Gjertsson, Rikard Holmdahl, Solbritt Rantapää‐Dahlqvist +12 morewiley +1 more sourceDeep Immunophenotyping Reveals Distinct Immune Signatures in Axial Spondyloarthritis and Psoriatic Arthritis
Arthritis &Rheumatology, Accepted Article.Objective
Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are overlapping yet distinct conditions within the spondyloarthritis (SpA) spectrum. As divergent immunophenotypes may influence disease course and therapeutic response, we compared immune cell subsets, cytokine profiles, and inflammatory mediators.Natalie Frede, Nils Craig‐Müller, Silke Kohrt, Marei‐Theresa Bott, Ulrich Salzer, Ana Cecilia Venhoff, Jens Thiel, Julia Frede, Reinhard E. Voll, Marta Rizzi, Raquel Lorenzetti, Nils Venhoff +11 morewiley +1 more sourceDeucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial
Arthritis &Rheumatology, Accepted Article.Objective
To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods
In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar +20 morewiley +1 more sourceClinico-Pathological Factors and AR-LBD Mutations in Early and Late Castration-Resistant Prostate Cancer
Cancer Management and ResearchMonu Deswal,1 Durgavati Yadav,1 Vinay Kumar,2 Meenakshi Meenu,3 Pranay Tanwar,4 Shivani Srivastava,5 Prabhjot Singh,1 Kumar Sandeep6 1Department of Urology, All India Institute of Medical Sciences, New Delhi, India; 2Heart and Vascular Institute ...Deswal M, Yadav D, Kumar V, Meenu M, Tanwar P, Srivastava S, Singh P, Sandeep K +7 moredoaj
